Investigating how IRS2 affects cell division in breast cancer
Official title: IRS2 and mitotic regulation in breast cancer
Funded at Univ of Massachusetts Med Sch Worcester · NIH-10996593 · Data updated 2026-11-12
This study is looking at how a protein called IRS2 affects cell division in triple negative breast cancer, with the hope of finding new ways to treat this aggressive type of cancer and improve options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $533,806 |
| NIH project number | 1R01CA290778-01A1 |
| Project ID | NIH-10996593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may benefit from novel therapeutic approaches.
✕Less likely to help
Patients with other types of breast cancer or those not diagnosed with breast cancer may not receive benefit from this research.
What this research studies
This research aims to understand the role of Insulin Receptor Substrate 2 (IRS2) in regulating the spindle assembly checkpoint, which is crucial for proper cell division. By focusing on triple negative breast cancer (TNBC), the study will explore how IRS2 contributes to the aggressive nature of this cancer subtype. The researchers will investigate the mechanisms by which IRS2 influences cancer cell growth and survival, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about targeting IRS2 for improved treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new therapies specifically targeting IRS2, improving outcomes for patients with triple negative breast cancer.
How similar studies have gone: While the specific targeting of IRS2 in TNBC is a novel approach, similar research has shown promise in understanding the role of signaling pathways in cancer progression.
Where this research is happening
-
Univ of Massachusetts Med Sch Worcester
Worcester, United States Active
Researchers
- Principal investigator: Shaw, Leslie M — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Shaw, Leslie M
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.